Molecular Partners (MOLN) AI Stock Analysis

• Market Cap: $159.77M
• Dividend Yield: N/A
• Average Volume (3M): 2.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: -100.00%
• EPS Growth: 11.02%
• Country: US
• Employees: 158
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 40,374,640
• 10 Day Avg. Volume: 2,377
• 30 Day Avg. Volume: 2,311
• PEG Ratio: 0.17
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 29.53
• P/FCF Ratio: -2.45
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.03
• Enterprise Value/Ebitda: -0.02
• 1Y Price Target: $8.00
• Price Target Upside: 95.12% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $4.50 ▲(9.76% Upside)

The overall stock score of 51 reflects significant financial challenges, including declining revenue and negative profitability margins, which are partially offset by positive technical indicators suggesting short-term bullish momentum. The negative P/E ratio and lack of dividend yield further weigh on the valuation.

Positive Factors

Clinical Pipeline Advancement

The advancement of MP0712 into clinical trials indicates progress in Molecular Partners' pipeline, potentially enhancing its market position and long-term growth prospects in oncology.

Strategic Partnerships

Strengthening partnerships, like with Orano Med, enhances Molecular Partners' operational capabilities and resource access, supporting long-term strategic goals and innovation.

Financial Stability

A robust cash position ensures Molecular Partners can sustain operations and invest in R&D without immediate external funding, supporting long-term strategic initiatives.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in market penetration or product sales, potentially impacting long-term financial health and operational sustainability.

Negative Profitability Margins

Ongoing negative profitability margins highlight operational inefficiencies and cost control issues, which could hinder long-term financial performance and growth.

Negative Free Cash Flow

Persistent negative free cash flow raises concerns about the company's ability to fund operations and growth internally, potentially leading to reliance on external financing.

Molecular Partners Business Overview & Revenue Model

Company Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

How the Company Makes Money

Molecular Partners generates revenue through a combination of strategic partnerships, research and development collaborations, and potential product sales. The company often enters into licensing agreements with larger pharmaceutical companies, providing them access to its DARPin technology in exchange for upfront payments, milestone payments tied to clinical and commercial achievements, and royalties on future sales. Additionally, the company may receive funding from grants or public investments aimed at supporting innovative biotech research. Key partnerships with major industry players can significantly enhance its financial resources and facilitate the development and commercialization of its products.

Molecular Partners Financial Statement Overview

Summary

Molecular Partners faces significant financial challenges, with declining revenue, negative profitability margins, and consistent net losses. While the balance sheet shows strong equity financing and low leverage, the company's cash flow and profitability issues raise concerns about its ability to sustain operations without external funding.

Income Statement

The company has experienced a decline in revenue over the past year, with a negative revenue growth rate of approximately -29.37% from 2023 to 2024. Gross profit margin is high at 100% in 2024 due to low total revenue, but net profit margin is negative due to substantial net losses, indicating challenges in controlling operational costs. EBIT and EBITDA margins are also negative, reflecting ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.02 in 2024, suggesting low leverage and financial risk. However, the equity ratio is high at 89.34%, indicating strong equity financing. Return on equity is negative due to net losses, which is a concern for profitability. Overall, the company has a solid equity base but struggles with profitability.

Cash Flow

The company reports negative free cash flow, which has slightly increased from the previous year's negative free cash flow. The operating cash flow to net income ratio is close to 1, indicating that cash flow performance aligns with net income losses. However, negative free cash flow is a concern for long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	4.97M	7.04M	189.56M	9.33M	9.34M
Gross Profit	-40.40M	-42.53M	-40.81M	138.81M	-46.39M	-46.73M
EBITDA	-58.02M	-51.65M	-59.52M	119.00M	-60.66M	-59.58M
Net Income	-60.24M	-54.04M	-61.98M	117.85M	-63.78M	-62.76M
Balance Sheet
Total Assets	112.15M	158.53M	198.35M	262.26M	172.67M	187.55M
Cash, Cash Equivalents and Short-Term Investments	104.52M	149.44M	186.89M	249.14M	132.81M	173.72M
Total Debt	1.53M	2.44M	3.65M	4.85M	6.04M	7.22M
Total Liabilities	16.62M	16.89M	21.92M	27.09M	65.38M	80.33M
Stockholders Equity	95.53M	141.64M	176.43M	235.17M	107.29M	107.22M
Cash Flow
Free Cash Flow	-54.01M	-59.97M	-59.81M	117.15M	-92.26M	-30.67M
Operating Cash Flow	-53.30M	-59.25M	-59.01M	118.57M	-90.95M	-28.98M
Investing Cash Flow	56.10M	40.49M	44.64M	-101.12M	-22.24M	-21.75M
Financing Cash Flow	14.45M	14.43M	-1.17M	-1.57M	50.58M	113.20M

Molecular Partners Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOLN, the sentiment is Positive. The current price of 4.1 is below the 20-day moving average (MA) of 4.14, above the 50-day MA of 3.89, and above the 200-day MA of 3.93, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 51.81 is Neutral, neither overbought nor oversold. The STOCH value of 22.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MOLN.

Molecular Partners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CGEN	52 Neutral	$148.72M	―	-52.95%	―	-88.47%	-1658.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOLN	51 Neutral	$159.77M	-2.05	-49.86%	―	-100.00%	11.02%
STTK	49 Neutral	$121.88M	-1.60	-57.84%	―	-84.46%	33.32%
CCCC	47 Neutral	$259.73M	―	-59.98%	―	-10.57%	1.98%
ONC	43 Neutral	―	―	―	―	―	―
NKTX	39 Underperform	$128.56M	―	-26.69%	―	―	25.84%

Molecular Partners Corporate Events

Molecular Partners Unveils Promising MP0712 Data at TRP Summit

On November 12, 2025, Molecular Partners presented new data on its lead Radio-DARPin, MP0712, targeting DLL3 at the TRP Summit Europe. The data included initial human images showing specific uptake in primary tumors and metastatic lesions, supporting the mechanism of action. The company is preparing for a Phase 1 trial in the US by the end of 2025, with initial data expected in 2026. This development marks a significant milestone in the clinical advancement of MP0712, potentially impacting the treatment of small cell lung cancer and other neuroendocrine cancers.

Molecular Partners Advances Clinical Pipeline with New IND Filing and Financial Update

On October 30, 2025, Molecular Partners announced its Q3 2025 financial results and clinical progress, highlighting the filing of an IND application for MP0712, a Radio-DARPin targeting DLL3, with a Phase 1 trial expected to start by the end of 2025. The company also shared updates on other programs, including MP0533 for AML and MP0317 for cholangiocarcinoma, alongside a strong financial position with a cash runway until 2028. These developments reflect Molecular Partners’ strategic advancements in oncology, potentially enhancing its industry standing and offering significant implications for stakeholders.

Molecular Partners Advances Clinical Programs and Strengthens Financial Position in H1 2025

Molecular Partners AG announced significant progress in its clinical programs and financial stability for the first half of 2025. The company is advancing its lead program MP0712 towards a first-in-human trial, with an IND filing expected by the end of 2025, and has presented promising data for its MP0533 program in treating acute myeloid leukemia. The expansion of its strategic partnership with Orano Med and the appointment of Martin Steegmaier as CSO further strengthen its operational capabilities. Financially, the company remains robust with funding secured into 2028, highlighting its strong market positioning and commitment to delivering value to stakeholders.